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the attending physician. Of a total of 393 patients, a final sample of 243 patients was included in the study: 109 patients (mean age: 60+/-17 years, 55% men; 66% with hypertension) in the ICCU group and 134 patients (mean age: 57+/-17 years; 56% men; 58% with hypertension) in the CCU group.
Study design
This was a case-control study, carried out in a single centre, the Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA. Although patients were prospectively admitted to the CCU or ICCU, the authors stated that the study was carried out retrospectively as auditing of data collection was conducted retrospectively. Patients were not followed after discharge from the hospital.
Analysis of effectiveness
The analysis was based on treatment completers only. The primary health outcome assessed in the analysis was a composite end point of death or MI after the first 24 hours. Secondary health outcomes were death, MI after the first 24 hours, major cardiac complications, such as congestive heart failure, ventricular tachycardia, or ventricular fibrillation. Study groups were shown to be comparable at baseline in terms of age, gender, and most clinical conditions. However, there was a statistically significantly higher frequency of tobacco users and a minor frequency of T-wave inversions in the ICCU group in comparison with CCU patients.
Effectiveness results
The effectiveness results were as follows:
The incidence of the composite end point of death or MI after the first 24 hours was 5% in the ICCU group and 3% in the CCU group, (p=0.511).
The incidence of MI was 5% in the ICCU group and 2% in the CCU group, (p=0.151).
The incidence of death was 0 in the ICCU group and 2% in the CCU group, (p=0.2).
The incidence of major cardiac complications was 17% in the ICCU group and 10% in the CCU group, (p=0.113).
Clinical conclusions
There was no statistically significant difference in any of the outcome measures used in the effectiveness analysis.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the economic analysis, as there were no statistically significant differences in any of the outcome measures. The benefits were, however, those reported in the effectiveness results above. The economic analysis was based, therefore on a cost-minimisation approach.
Direct costs
Discounting was not conducted as costs were incurred over a short period of time. Unit costs were not reported, but quantities of resources used were. The health services included in the economic evaluation were cardiac medications (aspirin, heparin, intravenous nitroglycerin, and beta-blockers), coronary angiography, percutaneous transluminal coronary angioplasty, coronary surgery, and length of hospital stay. The cost/resource boundary adopted was that of the hospital. The estimation of quantities was based on the effectiveness study. The main source of cost data was the hospital financial information system, which reported charges. A cost-to-charge ratio, specific to the study hospital, was then used to assess true costs of the service. Quantities of resources used were gathered between June 1992 and April 1994. No price year was reported.
